PolyPid Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

PolyPid wird ein Gewinn- und Umsatzwachstum von 4.4% bzw. 213.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 70% pro Jahr wachsen soll.

Wichtige Informationen

4.4%

Wachstumsrate der Gewinne

70.0%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	213.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

PolyPid set to cut 20% jobs

Oct 20

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

Sep 28

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

Sep 02

PolyPid GAAP EPS of -$1.23 misses by $0.60

Aug 10

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

Aug 03

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Mar 09

PolyPid's oncoplex cancer program shows encouraging action in animal study

Dec 22

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

Dec 16

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

Nov 24

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PYPD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	5	-24	N/A	N/A	2
12/31/2024	N/A	-27	N/A	N/A	2
6/30/2024	N/A	-25	-17	-17	N/A
3/31/2024	N/A	-24	N/A	N/A	N/A
12/31/2023	N/A	-24	-17	-17	N/A
9/30/2023	N/A	-24	N/A	N/A	N/A
6/30/2023	N/A	-28	-23	-22	N/A
3/31/2023	N/A	-34	N/A	N/A	N/A
12/31/2022	N/A	-40	-36	-34	N/A
9/30/2022	N/A	-46	N/A	N/A	N/A
6/30/2022	N/A	-47	-42	-39	N/A
3/31/2022	N/A	-46	N/A	N/A	N/A
12/31/2021	N/A	-43	-35	-32	N/A
9/30/2021	N/A	-41	N/A	N/A	N/A
6/30/2021	N/A	-37	-29	-28	N/A
3/31/2021	N/A	-46	N/A	N/A	N/A
12/31/2020	N/A	-43	-23	-22	N/A
9/30/2020	N/A	-42	N/A	N/A	N/A
6/30/2020	N/A	-37	N/A	N/A	N/A
3/31/2020	N/A	-19	-18	-17	N/A
12/31/2019	N/A	-13	-18	-17	N/A
12/31/2018	N/A	0	-20	-17	N/A
12/31/2017	N/A	-59	N/A	-12	N/A
9/30/2017	N/A	-20	N/A	-11	N/A
12/31/2016	N/A	-14	N/A	-10	N/A
12/31/2015	N/A	-11	N/A	-7	N/A
6/30/2014	N/A	-6	N/A	-3	N/A
3/31/2014	N/A	-5	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PYPD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PYPD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PYPD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PYPDDie Einnahmen des Unternehmens (213.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: PYPDDie Einnahmen des Unternehmens (213.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PYPD in 3 Jahren voraussichtlich hoch sein wird

PolyPid Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to US$3.38

Price target increased to US$24.33

Recent updates

PolyPid Ltd. to Report Q2, 2024 Results on Aug 14, 2024

PolyPid Ltd. Hosts Kol Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on Its Ongoing Shield II Phase 3 Trial

PolyPid Ltd., Annual General Meeting, Jul 02, 2024

PolyPid Ltd. Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. to Report Q1, 2024 Results on May 08, 2024

PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial

PolyPid Ltd. to Report Q4, 2023 Results on Feb 14, 2024

PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.

PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors

Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors

PolyPid Ltd. to Report Q3, 2023 Results on Nov 08, 2023

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PolyPid Announces Reverse Share Split to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement

PolyPid Ltd. Announces Successful Completion of Manufacturing Process Validation for D-PLEX100

PolyPid Ltd. to Report Q2, 2023 Results on Aug 09, 2023

Polypid Ltd. Announces New Publication Highlighting Potent Antibacterial Activity of D-Plex Against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

PolyPid Ltd. Announces Recruitment of First Patient in Revised Shield Ii Phase 3 Trial Evaluating D-Plex100 for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

PolyPid Ltd Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. Announces Board Changes

PolyPid Ltd. to Report Q4, 2022 Results on Feb 08, 2023

PolyPid Provides Positive Regulatory Update for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Polypid Ltd. Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-Hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

Price target decreased to US$3.38

PolyPid Ltd. to Report Q3, 2022 Results on Nov 09, 2022

PolyPid set to cut 20% jobs

Polypid Ltd. Announces Eligibility for European Medicines Agency Centralized Procedure for D-Plex100 for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX100 in the Prevention of Surgical Site Infections in Abdominal Surgery

Price target increased to US$24.33

PolyPid Ltd. Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

PolyPid GAAP EPS of -$1.23 misses by $0.60

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

PolyPid Ltd. to Report Q2, 2022 Results on Aug 10, 2022

Polypid Ltd Announces Completion of Enrollment in Phase 3 Shield I Trial of D-Plex for Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

PolyPid Ltd. Announces Executive Changes

PolyPid: Strong Pipeline, Close Catalysts

PolyPid Ltd. announced that it expects to receive $15 million in funding from Kreos Capital Management (UK) Limited

PolyPid Ltd., Annual General Meeting, May 03, 2022

Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

PolyPid Ltd. Announces 750Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 in Abdominal Surgery

PolyPid Ltd. Announces 750Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 in Abdominal Surgery

PolyPid Ltd. Announces CEO Changes

Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

PolyPid Ltd. Announces Positive FDA Type B Meeting Feedback for D-Plex Development Program

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid Ltd., Annual General Meeting, Apr 13, 2021

Polypid Ltd. Announces 100Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 for the Prevention of Post-Abdominal Surgery Incisional Infections

New 90-day high: US$12.75

PolyPid Ltd. to Report Q4, 2020 Results on Feb 10, 2021

PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program

PolyPid's oncoplex cancer program shows encouraging action in animal study

PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

New 90-day low: US$9.98

PolyPid Ltd. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: US$11.00

PolyPid Ltd. to Report Q2, 2020 Results on Aug 19, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken